IGC Pharma, Inc. announced encouraging preclinical results in an Alzheimer's mouse model demonstrating the potential of the Company's therapeutic candidate, TGR-63, to combat Alzheimer's disease. Alzheimer's disease is characterized by the buildup of abnormal protein aggregates in the brain, including amyloid plaques. These plaques are thought to play a major role in the cognitive decline and memory loss associated with the disease.

Current medications for Alzheimer's primarily focus on reducing or clearing amyloid plaque, highlighting its importance as a therapeutic target. These findings suggest TGR-63's potential to slow or even reverse the progression of Alzheimer's disease. Prior to in vivo studies, TGR-63 demonstrated its ability to disrupt the formation of toxic amyloid beta (Aß42) aggregates in cell cultures and increase the viability of neuronal cells exposed to Aß42, indicating potential neuroprotective effects.

TGR-63's unique structure allows it to interact with amyloid beta aggregates, potentially disrupting their structure and promoting their breakdown or clearance by the body's natural waste disposal systems. This could ultimately lead to a reduction in plaque burden in the brain, although there can be no assurance. The positive results from these preclinical studies could pave the way for advancing TGR-63 through clinical trials. IGC Pharma expects to begin a Phase 1 trial for TGR-63 in 2025, although there can be no assurance.